Latest Ratios: P/E Ratio -109.8x · EV/EBITDA N/A · ROE -13.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.1B | $1.5B | $729M | $293M | $420M | $386M | $715M | $702M | $759M | $943M | $276M |
| Enterprise Value | $3.1B | $1.5B | $771M | $331M | $472M | $421M | $720M | $671M | $734M | $931M | $271M |
| P/E Ratio → | -109.77 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.47 | 6.69 | 3.89 | 1.84 | 3.03 | 3.03 | 6.37 | 6.58 | 9.04 | 15.61 | 6.72 |
| P/B Ratio | 20.35 | 11.70 | 7.02 | 3.06 | 4.16 | 3.43 | 5.81 | 5.31 | 5.16 | 37.45 | 18.52 |
| P/FCF | 187.70 | — | 66306.53 | — | — | — | — | — | — | — | — |
| P/OCF | 3770.59 | 1856.19 | 160.83 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.84 | 4.11 | 2.08 | 3.41 | 3.30 | 6.42 | 6.29 | 8.75 | 15.41 | 6.58 |
| EV / EBITDA | — | 4474.73 | 169.34 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 70045.80 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.3% | 74.3% | 75.8% | 76.6% | 78.5% | 82.0% | 80.8% | 83.7% | 84.6% | 84.6% | 84.3% |
| Operating Margin | -3.5% | -3.5% | -1.8% | -13.5% | -21.4% | -20.0% | -20.6% | -29.4% | -24.4% | -13.2% | -19.8% |
| Net Profit Margin | -7.0% | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | -21.2% | -27.3% | -26.7% | -17.3% | -35.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -13.5% | -13.5% | -10.0% | -22.1% | -27.1% | -22.9% | -18.6% | -20.9% | -26.0% | -52.1% | -124.7% |
| ROA | -7.4% | -7.4% | -5.0% | -11.1% | -14.4% | -13.2% | -13.4% | -18.5% | -20.4% | -19.9% | -34.4% |
| ROIC | -3.8% | -3.8% | -1.8% | -11.2% | -14.8% | -13.8% | -15.2% | -21.0% | -22.6% | -52.9% | -71.5% |
| ROCE | -4.2% | -4.2% | -1.9% | -12.7% | -16.7% | -14.0% | -14.8% | -22.4% | -21.3% | -19.8% | -23.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.52 | 0.52 | 0.66 | 0.72 | 0.67 | 0.60 | 0.44 | 0.04 | 0.00 | 0.98 | 1.63 |
| Debt / EBITDA | 196.60 | 196.60 | 15.10 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.25 | 0.40 | 0.40 | 0.52 | 0.31 | 0.04 | -0.23 | -0.16 | -0.47 | -0.38 |
| Net Debt / EBITDA | 93.26 | 93.26 | 9.04 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | 3739.27 | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.04 | -1.04 | -0.21 | -6.66 | -45.39 | -18.90 | -21.57 | -727.38 | -17.54 | -3.24 | -1.30 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.11 | 5.11 | 3.24 | 2.89 | 4.13 | 5.23 | 6.36 | 6.47 | 11.57 | 4.06 | 3.97 |
| Quick Ratio | 3.31 | 3.31 | 2.16 | 2.14 | 3.33 | 4.54 | 5.81 | 5.80 | 10.65 | 3.53 | 3.48 |
| Cash Ratio | 1.51 | 1.51 | 1.09 | 1.02 | 2.05 | 3.46 | 4.55 | 4.62 | 8.94 | 2.66 | 2.71 |
| Asset Turnover | — | 1.02 | 0.92 | 0.81 | 0.71 | 0.61 | 0.56 | 0.69 | 0.52 | 1.03 | 0.89 |
| Inventory Turnover | 1.37 | 1.37 | 1.37 | 1.61 | 1.57 | 1.37 | 1.72 | 1.25 | 1.08 | 1.27 | 1.18 |
| Days Sales Outstanding | — | 42.41 | 46.97 | 57.72 | 58.43 | 52.04 | 57.26 | 57.96 | 66.62 | 66.84 | 71.50 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.5% | — | 0.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $46M | $44M | $43M | $42M | $41M | $40M | $39M | $37M | $33M | $31M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AXGN stock.
AxoGen, Inc.'s current P/E ratio is -109.8x. The historical average is 3.5x.
AxoGen, Inc.'s return on equity (ROE) is -13.5%. The historical average is -35.1%.
Based on historical data, AxoGen, Inc. is trading at a P/E of -109.8x. Compare with industry peers and growth rates for a complete picture.
AxoGen, Inc. has 74.3% gross margin and -3.5% operating margin.
AxoGen, Inc.'s Debt/EBITDA ratio is 196.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Persistent operating losses
Metrics are mathematically derived from official filings.
Premium Multiples Price Growth Not Earnings
Based on reported figures, AXGN trades at 11.94 times trailing sales and 90.24 times forward earnings, a premium that leaves little room for execution slippage given its still-negative trailing margins.
The negative trailing P/E of -147.12 is not meaningful for valuation, so the market appears to be anchoring on revenue growth and the forward P/E of 90.24 rather than current earnings power. The 17.88 price-to-book ratio is elevated relative to a company whose equity is largely built from contributed capital, which suggests investors are paying for the clinical moat and BLA optionality rather than asset backing. Investors should monitor whether forward earnings estimates compress toward the peer group, since the current premium implies growth expectations that the recent margin history does not yet support.
Gross Margin Strength Masks Operating Drag
As reported in financial statements, AXGN's gross margin has held between 71.9% and 76.6% over ten quarters, yet operating margin remained negative in three of the last four quarters, indicating SG&A absorbs nearly all gross profit.
The stability of the 74-75% gross margin suggests the proprietary processing advantage is structurally intact even as volumes scale. However, the gap between gross and operating margin points to a heavy commercial cost base, consistent with a direct sales force still funding surgeon education. The most recent operating margin of 1.3% is a first sign of leverage, but a single quarter is insufficient to conclude that operating leverage is durable.
Debt Retired Leaves Negligible Coverage Risk
Based on AXGN's reported figures, the debt-to-equity ratio fell from 0.52 to 0.04 and the current ratio rose to 12.02 in 2026Q3, indicating that balance sheet leverage is no longer a meaningful constraint.
Total debt held near $20M after exceeding $68M through 2025, which substantially reduces refinancing and covenant exposure relative to the prior period. Interest coverage figures are distorted by near-zero or negative operating income in earlier quarters, so coverage cannot be reliably trended. The lower leverage appears to reflect capital inflows rather than operating cash generation, which warrants monitoring of how the balance sheet is deployed.
Cash Reserves Dwarf Short-Term Obligations
As reported in financial statements, AXGN's quick ratio of 10.67 in 2026Q3 reflects a cash position of $328.9M against liabilities of $54.2M, suggesting ample capacity to absorb a severe operating shortfall.
Liquidity appears strong enough that near-term solvency is not a plausible concern under the reported figures. The more relevant question is how quickly the cash balance is consumed if operating losses return, since the quick ratio is a point-in-time measure and does not reflect burn rate. Investors should weigh the liquidity cushion against the historical volatility of quarterly cash flow.
Working Capital Cycle Lengthens Despite Growth
Based on reported quarterly figures, AXGN's cash conversion cycle has moved between 91 and 273 days over ten quarters, with DPO volatility driving most of the swing rather than receivables collection.
DSO has held in a relatively tight 40 to 47 day range, indicating customer collection behavior is stable. The sharp variation in DPO and resulting CCC suggests payables timing, not operational efficiency, is the main driver of quarterly working capital movement. Investors should treat the most recent 122-day CCC cautiously until payables timing normalizes.
Peer Multiples Overstate Comparable Value
According to recent SEC filings, AXGN's 90.24 forward P/E and 17.88 price-to-book sit far above peers such as MDXG and XTNT, whose profitable margins make their multiples a more grounded reference point.
The bull case relies on the BLA transition and clinical moat translating into durable margin expansion, yet the current multiples already discount a large share of that outcome. Comparing AXGN to profitable peers like MiMedx and Xtant, which trade near 10 times earnings, highlights how much of the valuation rests on future rather than present cash generation. Investors should test whether the premium remains defensible if BLA timing slips or if operating leverage fails to appear in coming quarters.